The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer

Immunotherapy encourages the recipient’s own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by bot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mouraviev, Vladimir, Mariados, Neil, Albala, David, Concepcion, Raoul S, Shore, Neal D, Sims, Robert B, Emberton, Mark, Pieczonka, Christopher M
Formato: Artigo
Lenguaje:Inglês
Publicado: MedReviews, LLC 2014
Materias:
Treatment Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191632/
https://ncbi.nlm.nih.gov/pubmed/25337042
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares